Simplex Trading
MYGN icon

Simplex Trading’s Myriad Genetics MYGN Stock Holding History

Simplex Trading’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.3K Buy
+1,400
New +$7.29K ﹤0.01% 7729
2025
Q4 		– Sell
-300
Closed -$2K – 9534
2025
Q3 		$2K Sell
300
-5,400
-95% -$32.1K ﹤0.01% 8679
2025
Q2 		$30K Buy
5,700
+4,600
+418% +$27.2K ﹤0.01% 6398
2025
Q1 		$9K Buy
+1,100
New +$13.2K ﹤0.01% 7179
2024
Q4 		– Sell
-10,600
Closed -$290K – 9226
2024
Q3 		$290K Sell
10,600
-2,300
-18% -$62.3K ﹤0.01% 4165
2024
Q2 		$315K Buy
12,900
+12,000
+1,333% +$263K ﹤0.01% 4168
2024
Q1 		$19K Sell
900
-900
-50% -$19.3K ﹤0.01% 7131
2023
Q4 		$34K Buy
+1,800
New +$31.1K ﹤0.01% 6456
2023
Q3 		– Sell
-100
Closed -$2K – 9407
2023
Q2 		$2K Buy
+100
New +$2.18K ﹤0.01% 8457
2023
Q1 		– Sell
-200
Closed -$2K – 9747
2022
Q4 		$2K Sell
200
-200
-50% -$3.73K ﹤0.01% 8614
2022
Q3 		$7K Sell
400
-200
-33% -$4.59K ﹤0.01% 8546
2022
Q2 		$10K Sell
600
-300
-33% -$6.23K ﹤0.01% 8297
2022
Q1 		$22K Sell
900
-400
-31% -$10.2K ﹤0.01% 8149
2021
Q4 		$35K Sell
1,300
-9,400
-88% -$272K ﹤0.01% 7700
2021
Q3 		$335K Hold
10,700
– – ﹤0.01% 4725
2021
Q2 		$327K Buy
10,700
+10,698
+534,900% +$309K ﹤0.01% 4833
2021
Q1 		$6K Sell
2
-22
-92% -$624 ﹤0.01% 8153
2020
Q4 		$47K Sell
24
-7
-23% -$113 ﹤0.01% 6249
2020
Q3 		$40K Sell
31
-8
-21% -$101 ﹤0.01% 5824
2020
Q2 		$44K Buy
39
+3
+8% +$43 ﹤0.01% 5612
2020
Q1 		$51K Sell
36
-273
-88% -$5.77K ﹤0.01% 5109
2019
Q4 		$841K Buy
309
+282
+1,044% +$7.76K ﹤0.01% 2244
2019
Q3 		$77K Sell
27
-465
-95% -$13.5K ﹤0.01% 4598
2019
Q2 		$1.37M Buy
492
+267
+119% +$7.54K ﹤0.01% 1622
2019
Q1 		$747K Buy
225
+216
+2,400% +$6.58K ﹤0.01% 2253
2018
Q4 		$26K Buy
9
+2
+29% +$72 ﹤0.01% 5129
2018
Q3 		$32K Sell
7
-28
-80% -$1.25K ﹤0.01% 5584
2018
Q2 		$130K Buy
35
+32
+1,067% +$1.08K ﹤0.01% 3974
2018
Q1 		$1K Buy
+3
New +$102 ﹤0.01% 5704
2017
Q3 		– Sell
-353
Closed -$25K – 6364
2017
Q2 		$25K Buy
353
+293
+488% +$6.22K ﹤0.01% 3089
2017
Q1 		$5K Sell
60
-161
-73% -$2.85K ﹤0.01% 4597
2016
Q4 		$6K Buy
221
+159
+256% +$2.88K ﹤0.01% 4202
2016
Q3 		$33K Sell
62
-33
-35% -$837 ﹤0.01% 2494
2016
Q2 		$24K Buy
95
+60
+171% +$2.08K ﹤0.01% 2735
2016
Q1 		$2K Buy
+35
New +$1.32K ﹤0.01% 4754
2015
Q4 		– Sell
-137
Closed -$51K – 5869
2015
Q3 		$51K Buy
137
+39
+40% +$1.38K ﹤0.01% 1980
2015
Q2 		$23K Buy
98
+5
+5% +$170 ﹤0.01% 2341
2015
Q1 		$18K Buy
93
+35
+60% +$1.25K ﹤0.01% 2418
2014
Q4 		$10K Buy
+58
New +$2.06K ﹤0.01% 2590

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Simplex Trading's MYGN Position: Q3 2025 in Review

Simplex Trading sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 14,791 shares — an estimated $87.8K sold.

Simplex Trading first reported a position in MYGN in Q2 2016 and held it in 26 quarters. The position peaked at $1.14M in Q2 2017. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

  • Simplex Trading reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
  • Simplex Trading sold 14,791 Myriad Genetics shares in Q3 2025, an estimated $87.8K.
  • Simplex Trading first reported a position in Myriad Genetics in Q2 2016 and held it in 26 quarters.
  • Simplex Trading's Myriad Genetics position peaked at $1.14M in Q2 2017.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Simplex Trading's 13F filing for Q3 2025, filed 12 Nov 2025.